Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience

The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine kinase inhibitor (TKI). However, the real-world evidence of benefits of EGFR TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chougule, Anuradha, Chandrani, Pratik, Noronha, Vanita, Pange, Priyanka, Kale, Shrutikaa, Nikam, Ankita, Nambiar, Kavya, Marchande, Dipika, Durve, Arpana, Gupta, Vinod, Jagtap, Vinita, Tiwrekar, Priyanka, Menon, Nandini, Joshi, Amit, Kaushal, Rajeev, Pai, Trupti, Patil, Vijay Maruti, Dutt, Amit, Banavali, Shripad Dinanath, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682910/
https://www.ncbi.nlm.nih.gov/pubmed/38033811
http://dx.doi.org/10.1016/j.jtocrr.2023.100566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682910/
https://www.ncbi.nlm.nih.gov/pubmed/38033811
http://dx.doi.org/10.1016/j.jtocrr.2023.100566

Ejemplares similares